Seaport Therapeutics, Inc. (NASDAQ:SPTX) Receives $35.50 Consensus Price Target from Analysts

Shares of Seaport Therapeutics, Inc. (NASDAQ:SPTX) have been given an average recommendation of “Moderate Buy” by the six analysts that are covering the stock, Marketbeat reports. Two analysts have rated the stock with a hold rating and four have issued a buy rating on the company. The average 1 year price target among brokers that have issued ratings on the stock in the last year is $35.50.

Several research firms have recently weighed in on SPTX. Citigroup started coverage on shares of Seaport Therapeutics in a report on Tuesday. They issued a “buy” rating and a $35.00 price target on the stock. Seaport Research Partners set a $42.00 price objective on Seaport Therapeutics in a research note on Tuesday. Stifel Nicolaus started coverage on Seaport Therapeutics in a research note on Tuesday. They set a “buy” rating and a $30.00 price objective for the company. Zacks Research raised Seaport Therapeutics to a “hold” rating in a research note on Wednesday. Finally, JPMorgan Chase & Co. started coverage on Seaport Therapeutics in a research note on Tuesday, May 26th. They set an “overweight” rating and a $42.00 price objective for the company.

Seaport Therapeutics Price Performance

Shares of Seaport Therapeutics stock opened at $18.19 on Tuesday. Seaport Therapeutics has a 12-month low of $14.85 and a 12-month high of $23.00.

Insiders Place Their Bets

In related news, major shareholder Arch Venture Partners Xii, Llc bought 1,100,000 shares of the stock in a transaction that occurred on Monday, May 4th. The shares were acquired at an average cost of $18.00 per share, with a total value of $19,800,000.00. Following the completion of the purchase, the insider directly owned 6,294,951 shares of the company’s stock, valued at $113,309,118. This trade represents a 21.17% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this hyperlink.